Vivo Capital’s Dyne Therapeutics DYN Stock Holding History

Vivo Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.2M	Sell	1,557,466 -1,057,494	-40%	-$18.2M	2.35%	13
2025 Q4	$51.1M	Hold	2,614,960	–	–	3.31%	8
2025 Q3	$33.1M	Buy	2,614,960 +1,500,000	+135%	+$17.1M	2.66%	12
2025 Q2	$10.6M	Hold	1,114,960	–	–	1.09%	16
2025 Q1	$11.7M	Hold	1,114,960	–	–	1.54%	10
2024 Q4	$26.3M	Hold	1,114,960	–	–	2.94%	6
2024 Q3	$40M	Sell	1,114,960 -520,176	-32%	-$20.7M	3.31%	8
2024 Q2	$57.7M	Hold	1,635,136	–	–	5.33%	5
2024 Q1	$46.4M	Buy	1,635,136 +600,000	+58%	+$13.6M	3.65%	8
2023 Q4	$13.8M	Hold	1,035,136	–	–	1.13%	17
2023 Q3	$9.27M	Buy	1,035,136 +457,494	+79%	+$4.93M	1.02%	25
2023 Q2	$6.5M	Hold	577,642	–	–	0.45%	31
2023 Q1	$6.65M	Hold	577,642	–	–	0.46%	28
2022 Q4	$6.7M	Hold	577,642	–	–	0.77%	28
2022 Q3	$7.34M	Hold	577,642	–	–	0.81%	32
2022 Q2	$3.97M	Hold	577,642	–	–	0.4%	42
2022 Q1	$5.57M	Hold	577,642	–	–	0.38%	42
2021 Q4	$6.87M	Hold	577,642	–	–	0.41%	42
2021 Q3	$9.38M	Hold	577,642	–	–	0.42%	40
2021 Q2	$12.2M	Hold	577,642	–	–	0.53%	35
2021 Q1	$8.97M	Buy	577,642 +262,642	+83%	+$5.08M	0.32%	45
2020 Q4	$6.62M	Hold	315,000	–	–	0.3%	47
2020 Q3	$6.36M	Buy	+315,000	New	+$6.91M	0.37%	48

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Vivo Capital's DYN Position: Q1 2026 in Review

Vivo Capital reduced its Dyne Therapeutics (DYN) stake by 40% in Q1 2026, selling an estimated $18.2M and leaving 1,557,466 shares worth $28.2M. The position accounts for 2.35% of the portfolio, ranked #13.

Vivo Capital first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $57.7M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Vivo Capital held 1,557,466 shares of Dyne Therapeutics worth $28.2M as of Q1 2026.
Vivo Capital sold 1,057,494 Dyne Therapeutics shares in Q1 2026, an estimated $18.2M.
Dyne Therapeutics made up 2.35% of Vivo Capital's portfolio in Q1 2026, its #13 holding.
Vivo Capital first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
Vivo Capital's Dyne Therapeutics position peaked at $57.7M in Q2 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.